Effect of CYP3A5 * 3 polymorphism on the dose of sufentanil in patients undergoing laparoscopic cholecystectomy

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800020169

Enrollment

Unknown

Registered

2018-12-19

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholecystitis

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) 120 patients undergoing laparoscopic cholecystectomy under general anesthesia; (2) Han nationality, age 18-60 years old, ASA grade I to III, operation time <2H, body mass index 18-25kg/m2.

Exclusion criteria

Exclusion criteria: (1) History of smoking and alcohol abuse; (2) Have a history of severe circulatory system, liver, kidney, and diabetes; (3) History of chronic pain and long-term use of analgesics; (4) taking a metabolic enzyme inhibitor or inducer within the last month; (5) Those who are allergic to sufentanil or other opioids; (6) bronchial asthma or myasthenia gravis patients; (7) Patients who are pregnant or breast-feeding.

Design outcomes

Primary

Measure	Time frame
Gene Sequencing;Sufentanil dosage;Sufentanil dosage;	—

Countries

China

Contacts

Public ContactZhan Leyun

China Three Gorges University

Leyunzhan@163.com+86 13872591759

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026